专利检索 ap:("SORBONNE UNIVERSITE" OR "CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE" OR "INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)") AND inv:"Philippe Karoyan" 第 1 页

1.

发明授权
Agents that activate CD47 and their use in the treatment of inflammation 有权

公开(公告)号：US11142548B2

公开(公告)日：2021-10-12

申请号：US16300438

申请日：2017-05-10

申请人： SORBONNE UNIVERSITE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

发明人： Florian Sennlaub , Michael Housset , Xavier Guillonneau , José-Alain Sahel , Philippe Karoyan

IPC分类号： A61K38/00 , C07K7/08 , A61K38/16 , A61P27/02 , A61P29/00

摘要： Disclosed are agents activating CD47 and their use in the treatment of inflammation, in particular non-resolving low grade inflammation, characterized by chronic MP infiltration, such as age-related macular degeneration. Also disclosed are pharmaceutical compositions, medicaments and kits including the agents.

2.

发明申请
AGONIST AGENTS OF CD47 INDUCING PROGRAMMED CELL DEATH AND THEIR USE IN THE TREATMENTS OF DISEASES ASSOCIATED WITH DEFECTS IN PROGRAMMED CELL DEATH 审中-公开

公开(公告)号：US20190135865A1

公开(公告)日：2019-05-09

申请号：US16099997

申请日：2017-05-10

申请人： SORBONNE UNIVERSITE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

发明人： Philippe Karoyan

IPC分类号： C07K7/50 , C07K7/64 , A61P37/06 , A61P29/00

摘要： The present invention relates to cyclic peptides mimetics of the C-terminal binding domain of TSP-1. The present invention also relates to the use of these cyclic peptides as agonists of CD47 and their ability to trigger programmed cell death (PCD). The present invention further relate to a pharmaceutical composition for use in the treatment of diseases associated with defects in PCD such as cancers and immunological disorders (including chronic inflammation) and comprising at least one cyclic peptide according to the invention.

3.

发明授权
Agonist agents of CD47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death 有权

公开(公告)号：US11306124B2

公开(公告)日：2022-04-19

申请号：US16099997

申请日：2017-05-10

申请人： SORBONNE UNIVERSITE , Centre National de la Recherche Scientifique

发明人： Philippe Karoyan

IPC分类号： C07K7/50 , C07K7/64 , A61P37/06 , A61P29/00 , A61K38/00 , C07K14/47 , C07K14/705

摘要： The present invention relates to cyclic peptides mimetics of the C-terminal binding domain of TSP-1. The present invention also relates to the use of these cyclic peptides as agonists of CD47 and their ability to trigger programmed cell death (PCD). The present invention further relate to a pharmaceutical composition for use in the treatment of diseases associated with defects in PCD such as cancers and immunological disorders (including chronic inflammation) and comprising at least one cyclic peptide according to the invention.

4.

发明申请
NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER 审中-公开

公开(公告)号：US20190144501A1

公开(公告)日：2019-05-16

申请号：US16099974

申请日：2017-05-10

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA REC HERCHE MÉDICALE) , UNIVERSITE PARIS DESCARTES , SORBONNE UNIVERSITE , UNIVERSITÉ PARIS DIDEROT - PARIS 7

发明人： Santos A. Susin , Philippe Karoyan , Hélène Merle-Beral

IPC分类号： C07K7/06 , A61P35/00

摘要： The present invention relates to a compound or a pharmaceutical salt thereof comprising a hexapeptide sequence of formula (I), its method of synthesis and its use in anticancer therapy. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.